Health & Life Technologies

“The Health category, in addition to therapies, diagnostics and medical devices, also covers sport and well-being and targets research results with strong transfer potential. It is challenged by market demand; and we are carrying out targeted monitoring, issuing Calls for Expressions of Interest, and consulting academic and industrial experts. The “Prostate cancer antisense” project is a novel approach using synthetic therapeutic DNA to block a target expressed in prostate cancer; this project is co-financed by Inserm Transfert.
The sport and well-being sub-category is looking promising in the context of Marseille-Provence being European Capital of Sport in 2017.”


sCD146 IVF Implantation Biomarker Competitive embryos for infertile parents

What is it? An embryo selection biomarker with the best implantation potential.
For which field of application? Improve the success rates in in vitro fertilization.
Who invented it? Laboratoire d’Histologie-Embryologie-Biologie de la Reproduction, Laboratoire d’Immunologie de La Conception, Laboratoire de Physiopathologie de l’Endothélium (Inserm U1076), AP-HM, CHU de Nîmes, Université de Montpellier
Who participated? Aix-Marseille Université, Inserm, AP-HM
Maturation status: Industrial validation
+ Co-maturation and sublicense agreements have been signed with Diasys Technologies, a subsidiary of the DiaSys Diagnostics Systems Group (Germany), a leader in the field of diagnostics.

BISE – Innovation in MRI myelin imaging

What is it? BISE, an in vivo myelin quantitative imaging technique, the substance used to isolate and protect nerve fibers.
For which field of application? To diagnose demyelinating conditions and evaluate therapies for multiple sclerosis and other central nervous system conditions.
Who invented it? Centre de Résonance Magnétique Biologique et Médicale (CRMBM)
Who participated? Aix-Marseille Université, CNRS, Institut Carnot STAR

Vertigo : A treatment for balance disorders linked to the inner ear

What is it? A potential anti-vertigo drug candidate.
For which field of application? To treat the symptoms of a condition that affects one in three people with vestibular disorders.
Who invented it? Laboratoire de Neurosciences Intégratives et Adaptatives (LNIA)
Who participated? Aix-Marseille Université, CNRS

dendriTAC – Nanoemulsions to destroy cancerous tumors

What is it? The development of the first Tgammadelta precision cancer immunotherapy.
For which field of application? The treatment of solid and hematological cancers, including pancreatic adenocarcinoma.
Who invented it? Institut des Biomolécules Max Mousseron (IBMM UMR 5247a), Laboratoire d’Imagerie Biomédicale (LIB UMR-S 1146, UMR 7371), Laboratoire Physique Statistique (LPS UMR 8550)
Who participated? Université d’Avignon et des Pays de Vaucluse, CNRS, UPMC, Inserm, Université Montpellier 1 et 2, ENSCM, ENS, Université Paris Diderot et Université Paris V

Supervised Segmentation of MRI Images Advanced muscle disease diagnosis by imaging

What is it? Image processing software for MRI muscle supervised segmentation.
For which field of application? Monitoring of muscular diseases, including sarcopenia (reduction of muscle mass in the elderly) the improvement of sports training and the determination of the effectiveness of therapeutic strategies.
Who invented it? Centre de Résonance Magnétique Biologique et Médicale (CRMBM)
Who participated? Aix-Marseille Université, CNRS, Institut Carnot STAR

Atherosclerosis diagnosis: Centre Méditerranéen de Médecine Moléculaire (C3M, Université Nice Sophia Antipolis, Inserm, U1065), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC, Inserm, UMR 1048)

Development of a biomarker to prevent an initial heart attack in populations predisposed to Acute Coronary Syndrome (ACS) before rupture of the atherosclerotic plaque.

ISA method and re-encoding of viruses: Laboratoire Emergence des Pathologies Virales (EPV, Aix-Marseille Université, Inserm, IRD, U190)

New process for obtaining vaccines from attenuated viruses. The maturation program focuses on candidate vaccines for veterinary use, with an assessment of their production yield and their infectiousness.

Pluripotent cell differentiation process: Laboratoire Génétique Médicale et Génomique Fonctionnelle (Aix-Marseille Université, Inserm, UMR_S910)

The maturation program should make it possible to produce predictive models of different types of neuronal cells from human-induced pluripotent stem cells. The aim is to propose non-toxicity tests of drug candidates or to confirm their effectiveness on neurodegenerative human models.

Prostate Cancer Antisens: Centre de Recherche en Cancérologie de Marseille (CRCM, Aix-Marseille Université, CNRS, Inserm, U1098)

The aim of the project is to demonstrate the effectiveness of therapeutic synthetic DNAs that interact with a mRNA encoding for a protein expressed during tumor development. The purpose of this program is to slow down the development of tumors and reduce resistance to hormone treatments and chemotherapies.

M-CSF: Centre d’Immunologie Marseille-Luminy (CIML, Aix-Marseille Université, CNRS, Inserm, U6102)

Preventive and curative treatment designed to strengthen and speed up restoration of the immune system in immunedepressed patients who have received stem cell grafts. This treatment can be used to prevent the development of fungal, viral or bacterial infections that accompany this type of transplant.

Dengue antivirals: Laboratoires Architecture et Fonction des Macromolécules Biologiques (AFMB, Aix-Marseille Université, CNRS, UMR 7257), Émergence des Pathologies Virales (EPV, Aix-Marseille Université, Inserm, UMR_S190)

4 serotypes of the Dengue virus compared to molecules that have been developed, or are under development, by pharmaceutical or biotech companies.

Asian Tiger Mosquito sucking blood on human skin (albopictus)